HVB MINI FUTURE BULL - ASTRAZENECA | Real-time BOERSE MUENCHEN 01:16:51 16/05/2024 am IST | ||
| 6.56 EUR | -1.35% |
|
| Current month | +3.42% | ||
| 1 month | +26.91% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 16/24/16 | 6.56 | -1.35% |
| 14/24/14 | 6.65 | -0.45% |
| 13/24/13 | 6.68 | -1.18% |
| 10/24/10 | 6.76 | -0.29% |
| 09/24/09 | 6.78 | +1.35% |
Real-time BOERSE MUENCHEN
Last update May 16, 2024 at 01:16 am IST
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
UniCredit
|
| WKN | HR5TXX |
| ISIN | DE000HR5TXX4 |
| Date issued | 25/02/2021 |
| Strike | 6,538 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.42 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7 € |
|---|---|
| Lowest since issue | 1.04 € |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
154.2
USD
Average target price
167.4
USD
Spread / Average Target
+8.59%
- Stock Market
- Certificates
- Certificat
